Overview

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Status:
Completed
Trial end date:
2019-10-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether neratinib can further reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer after adjuvant treatment with trastuzumab.
Phase:
Phase 3
Details
Lead Sponsor:
Puma Biotechnology, Inc.
Treatments:
Trastuzumab